memantale-instruction
memantale-instruction

MEMANTALE [Memantine]

Clear
Bulk deal
Quantity Discount Discounted price
2 10% -
3 14% -
4 16% -
5 + 18% -
Bulk pricing will be applied to package:

Buy Memantine 10mg with 3-7 day fast domestic delivery within the US ($5) – just choose “ships from US (+15%) 

Synthesised by Eli Lilly and Company in 1968, Memantine is one of the few pharmaceuticals approved by FDA to be used treatment of moderate-to-severe Alzheimer’s disease. Off-label Memantine can also be used for reversing tolerance for caffeine, nicotine and opioids; it might also be taken for a treatment of generalized anxiety disorder.

In the body Memantale reduces certain types of brain activity by binding to NMDA receptors and blocking the activity of glutamate. As a result it upregulates receptors in the brain and has a cognitive-enhancing effect.

Side effects: The medication is, in general, well-tolerated. Side effects are likely to occur if the dosage accumulated in the body is too high. Memantine side effects include confusion, drowsiness, headache, agitation and hallucinations.

Note: Supplement half-life is 60-100 hours, therefore caution should be exerted when tapering up after first days of use.

Country of Manufacture: Russia

Check out other nootropics.


Legal Disclaimer
This product has not been approved by the US FDA. All statements on this page are for informational purposes only and have not been evaluated by the US FDA.
This product is not intended to diagnose, treat, cure, or prevent any disease. See more

Dosage: Memantine starting dosage is 5 mg daily, which can slowly be tapered up to 10-15 mg, depending on the indication.

Country of Manufacture: Russia

  1. M Rogawski, G Wenk (2003) The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/14530799
  2. Reisberg et al (2003) Memantine in moderate-to-severe Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/12672860
  3. Mobius et al (2004) Memantine hydrochloride: pharmacological and clinical profile https://www.ncbi.nlm.nih.gov/pubmed/15510240
  4. R Tampi, C van Dyck (2007) Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654628/
  5. Charles et al (2007) Memantine for prevention of migraine: a retrospective study of 60 cases https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3451671/
  6. H Kavirajan, L Schneider (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials https://www.ncbi.nlm.nih.gov/pubmed/17689146
  7. Farlow et al (2008) Memantine for the treatment of Alzheimer’s disease: tolerability and safety data from clinical trials https://www.ncbi.nlm.nih.gov/pubmed/18558791
  8. Porsteinsson et al (2008) Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial https://www.ncbi.nlm.nih.gov/pubmed/18288936
  9. Clerici et al (2009) Memantine in moderately-severe-to-severe Alzheimer’s disease: a postmarketing surveillance study https://www.ncbi.nlm.nih.gov/pubmed/19476399
  10. S Thomas, G Grossberg (2009) Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762361/
  11. Howard et al (2012) Donepezil and memantine for moderate-to-severe Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/22397651
  12. Yang et al (2013) Effectiveness and safety of memantine treatment for Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/23635410
  13. Dysken et al (2014) Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease The TEAM-AD VA Cooperative Randomized Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109898/
  14. Nakamura et al (2014) Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer’s disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025599/
  15. Matsunaga et al (2015) Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis https://www.ncbi.nlm.nih.gov/pubmed/25860130
  16. Atri et al (2015) Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436119/
  17. Hager et al (2016) Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study https://www.ncbi.nlm.nih.gov/pubmed/27846868
  18. Marimuthu et al (2016) Evaluating the efficacy of memantine on improving cognitive functions in epileptic patients receiving anti-epileptic drugs: A double-blind placebo-controlled clinical trial (Phase IIIb pilot study) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980957/
  19. Kishi et al (2017) Memantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis https://www.ncbi.nlm.nih.gov/pubmed/28922160
  20. Karahmadi et al (2017) Study of the effect of Memantine therapy on the treatment of dyslexia in children https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767814/
  21. N Titova et al (2017) Memantine: from the original brand to generics https://www.ncbi.nlm.nih.gov/pubmed/29171502
  22. Folch et al (2018) Memantine for the Treatment of Dementia: A Review on its Current and Future Applications https://www.ncbi.nlm.nih.gov/pubmed/29254093
  23. Tavakoli-Ardakani et al (2018) Study of the Effect of Memantine on Negative Sign in Patients with Schizophrenia and Schizoaffective Disorders https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958331/

Related products

CYCLOFERON ®

$ 10.00$ 35.00

Cycloferon is an antiviral and immunomodulating drug that has been used in the pharmacological practice for over 20 years, since 1992. The active ingredient is meglumine acridone acetate, which is effective against not only viruses, but also bacteria and fungi.

ARBIDOL ® (Umifenovir)

$ 26.00$ 50.00

Arbidol is a broad-spectrum antiviral compound developed in USSR in 1974. Arbidol demonstrates activity against a number of enveloped and non-enveloped viruses.В It is used for the prevention and treatment of influenza and other acute respiratory viral infections in adults and children.В Arbidol may also be immunomodulatory, and as such be capable of interferon induction and/or macrophage activation.

Aralia is a well-known gentle adaptogenic tonic herb popular for its wide range of pharmacological properties. It is used to treat physical and mental fatigue, asthenic syndrome, arterial hypotension, decreased sex drive, mental breakdown, depression, enuresis, radiation sickness and metabolic disorders. ThisВ herbal remedy can also help to recover from craniocerebral injury, contusion, meningitis, post-infectious arachnoiditis and ARVI (in the complex therapy).

Apilak is a honey bee secretion from the glands in the hypopharynx of nurse bees. It contains a wide range of important vitamins (C, B1, B2, B5, B6, B8, B12, H, folate and inositol), minerals (K, Na, Ca, Mg, Fe and P), trace elements (Zn, Mn, Cu, Co, S, Si, Ni, Cr, As and Bi) and amino acids. Drug activates the immune system in the recovery after illnesses, improves metabolism and function of nervous and endocrine systems.